Pathstone Holdings LLC Acquires 5,459 Shares of Repligen Co. (NASDAQ:RGEN)

Pathstone Holdings LLC grew its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 32.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 22,284 shares of the biotechnology company's stock after buying an additional 5,459 shares during the period. Pathstone Holdings LLC's holdings in Repligen were worth $3,316,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the business. Andra AP fonden purchased a new position in shares of Repligen in the 2nd quarter worth about $25,000. International Assets Investment Management LLC purchased a new position in shares of Repligen in the 2nd quarter worth about $33,000. UMB Bank n.a. raised its position in shares of Repligen by 138.3% in the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company's stock worth $33,000 after purchasing an additional 130 shares during the last quarter. Lazard Asset Management LLC raised its position in shares of Repligen by 206.1% in the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company's stock worth $36,000 after purchasing an additional 136 shares during the last quarter. Finally, Blue Trust Inc. raised its position in Repligen by 113.4% in the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company's stock worth $36,000 after buying an additional 127 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

Insiders Place Their Bets

In related news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the sale, the director now owns 139,840 shares in the company, valued at approximately $20,328,540.80. This represents a 13.70 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 1.20% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on RGEN. UBS Group decreased their target price on Repligen from $205.00 to $185.00 and set a "buy" rating for the company in a research report on Wednesday, July 31st. Wells Fargo & Company began coverage on Repligen in a research report on Tuesday, August 27th. They issued an "overweight" rating and a $180.00 target price for the company. StockNews.com raised Repligen from a "sell" rating to a "hold" rating in a research report on Friday. Royal Bank of Canada reissued an "outperform" rating and issued a $205.00 target price on shares of Repligen in a research report on Thursday, September 26th. Finally, Wolfe Research started coverage on Repligen in a research report on Thursday, November 14th. They issued a "peer perform" rating for the company. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $190.25.

Repligen Stock Performance

Shares of NASDAQ:RGEN traded up $3.48 during mid-day trading on Monday, reaching $146.06. 578,058 shares of the company traded hands, compared to its average volume of 669,038. The company's 50 day moving average price is $140.26 and its 200-day moving average price is $143.12. The firm has a market cap of $8.18 billion, a PE ratio of -394.59, a PEG ratio of 4.29 and a beta of 0.96. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. Repligen Co. has a 52 week low of $113.50 and a 52 week high of $211.13.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.34 by $0.09. The company had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The firm's revenue was up 9.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.23 EPS. On average, equities analysts expect that Repligen Co. will post 1.52 EPS for the current fiscal year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.